Answers are grounded in this paper and cite their sources.
Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.
No takes yet. Share an insight, caveat, or question.
Inati et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: